Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stroke prevention in atrial fibrillation

J L Halperin1, E B Rothlauf

  • 1Department of Medicine, Mount Sinai Medical Center, New York, New York 10029.

The Mount Sinai Journal of Medicine, New York
|September 1, 1993
PubMed
Summary

Atrial fibrillation (AF) increases stroke risk significantly. Identifying low-risk patients allows for personalized prevention strategies, balancing stroke reduction with bleeding risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.

Journal of thrombosis and haemostasis : JTH·2015
Same author

A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).

Journal of thrombosis and haemostasis : JTH·2015
Same author

Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.

International journal of clinical practice·2015
Same author

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Journal of clinical pharmacology·2014
Same author

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?

Journal of thrombosis and haemostasis : JTH·2012

Area of Science:

  • Cardiology
  • Neurology
  • Thrombosis Research

Background:

  • Atrial fibrillation (AF) is a major risk factor for ischemic stroke, increasing lifetime risk by 35%.
  • Current prophylactic treatments like warfarin carry bleeding risks, and aspirin shows variable efficacy, particularly in older adults.
  • Optimal antithrombotic prophylaxis selection for AF patients remains a clinical challenge.

Purpose of the Study:

  • To identify predictors of thromboembolism in AF patients.
  • To enable individualized antithrombotic approaches based on patient-specific risk factors.
  • To optimize stroke prevention while minimizing hemorrhagic complications in AF patients.

Main Methods:

  • Secondary analysis of placebo group patients from randomized trials.
  • Identification of clinical predictors (hypertension, heart failure, prior stroke/TIA) and echocardiographic findings (left ventricular dysfunction, left atrial enlargement).

Main Results:

  • Specific clinical and echocardiographic features predict thromboembolism risk in AF.
  • A subgroup of AF patients with none of these risk factors exhibits a comparatively low stroke risk.
  • These findings suggest anticoagulation may not be warranted for all AF patients.

Conclusions:

  • Individualized antithrombotic strategies are crucial for AF patients.
  • Risk stratification using clinical and echocardiographic data can guide prophylaxis selection.
  • Balancing therapeutic benefit and hemorrhagic risk is key to managing stroke in AF.

Related Experiment Videos